CardioBites: SGLT2is

CardioBites are mobile-friendly, bite-sized videos providing focused education on important topics in the heart failure field.

The 2022 American Heart Association/American College of Cardiology/Heart Failure Society of America Guideline for the Management of Heart Failure includes 4 classes of medication for guideline-directed medical therapy. Guidance for sodium-glucose cotransporter-2 inhibitors (SGLT2is) is now included for some patients. Learn more about the burden of heart failure, and how the guidelines recommend incorporating these therapies to improve our patients’ quality of life in the CardioBites Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) series that was released between March 2024 and August 2024.

 

 

 

Videos in the Series

Coming in March 2024
Understanding the burden of heart failure
Coming in April 2024
Current guidelines on the use of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) in HF
Coming in May 2024
The Impact of Hospital Readmissions on Health-Related Quality of Life in Heart Failure
Coming in June 2024
Improving the Transition of Care in Heart Failure
Coming in July 2024
Why guideline-directed medical therapy in heart failure matters
CardioBites SGLT2is Infographic
Understanding the burden of heart failure-Infographic

Support for this program was provided by an independent grant from Lexicon Pharmaceuticals, Inc.

About CardioBites

CardioBites are mobile-friendly, bite-sized videos providing focused education on important topics in the heart failure field. They can be watched anytime, anywhere on YouTube. No password. No barriers. Just easy access. Each CardioBites series is designed to educate physicians, scientists, nurses, nurse practitioners, pharmacists, and patients about the recent advances and emerging trends in Heart Failure. Learn More.